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High-Level Expression of Glycoprotein D by a
Dominant-Negative HSV-1 Virus Augments its
Efficacy as a Vaccine against HSV-1 Infection
Zheming Lu1,2, Richard Brans1,2, Natali V. Akhrameyeva1, Nao Murakami1, Ximing Xu1 and Feng Yao1,2
Using the T-REx (Invitrogen, Carlsbad, CA) gene switch technology, we previously generated a dominant-
negative herpes simplex virus (HSV)-1 recombinant, CJ83193, capable of inhibiting its own replication as well as
that of wild-type HSV-1 and HSV-2. It has been further demonstrated that CJ83193 is an effective vaccine against
HSV-1 infection in a mouse ocular model. To ensure its safety and augment its efficacy, we generated an
improved CJ83193-like HSV-1 recombinant, CJ9-gD, which contains a deletion in an HSV-1 essential gene and
encodes an extra copy of gene-encoding glycoprotein D (gD) driven by the tetO-bearing human
cytomegalovirus major immediate-early promoter. Unlike CJ83193, which exhibits limited plaque-forming
capability in Vero cells and expresses little gD in infected cells, CJ9-gD is completely replication defective, yields
high-level expression of gD following infection, and cannot establish detectable infection in mouse trigeminal
ganglia following intranasal and ocular inoculation. Mice immunized with CJ9-gD produced 3.5-fold higher
HSV-1 neutralizing antibody titer than CJ83193-immunized mice, and were completely protected from herpetic
ocular disease following corneal challenge with wild-type HSV-1. Moreover, immunization of mice with CJ9-gD
elicited a strong HSV-1-specific T-cell response and led to an 80% reduction in latent infection by challenge
wild-type HSV-1 compared with the mock-immunized control.
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INTRODUCTION
The major clinical significance of herpes simplex virus
type 1 and type 2 (HSV-1 and -2) is their ability to cause
acute primary infection and to reactivate periodically from
latency and cause recurrent infection. Although HSV infec-
tions are often asymptomatic, their clinical manifestations
include orofacial infections, genital herpes, neonatal herpes,
keratoconjunctivitis, and herpes encephalitis (Whitley et al.,
1998; Stanberry et al., 2000; Koelle and Ghiasi, 2005). HSV-
2 is the primary cause of genital ulcer disease. HSV-1
infection often associates with orofacial blisters and herpetic
ocular disease, which is the leading cause of virus-induced
blindness in developed as well as less developed countries
(Group THEDS, 1998; Kovac-Kovacic and Skaleric, 2000;
Xu et al., 2002). Notably, there has been a significant
increase in HSV-1-related genital herpes in recent years
and in some developed countries or populations, HSV-1
infection has become a common cause of genital herpes
(Lafferty et al., 2000; Lowhagen et al., 2000; Nilsen and
Myrmel, 2000; Ribes et al., 2001; Scoular et al., 2002;
Tran et al., 2004; Roberts, 2005). Although the severity
of most symptomatic HSV infections can be reduced by
antiviral treatment, there is no effective medication that
can prevent primary HSV infections nor decrease the
incidence of recurrences except for daily suppressive therapy.
Thus, there is a strong need for a safe and effective vaccine
against HSV infections (Stanberry, 2004; Koelle and Corey,
2008).
HSV gene expression was classified into three major
phases during productive infection, named immediate-early
(a), early (b), and late (g), with late genes being further divided
into two groups, g1 and g2 (Roizman and Knipe, 2001). The
expression of a genes requires no de novo protein synthesis
and is activated by the virion-associated protein VP16
together with cellular transcription factors (Roizman and
Knipe, 2001). Although the expression of viral a and b genes
does not depend on viral DNA replication, expression of g
genes is highly influenced by de novo viral DNA synthesis.
Specifically, de novo viral DNA replication leads to increased
expression of g1 genes and inhibition of viral DNA
replication blocks expression of g2 genes.
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Safety and efficiency in eliciting an effective host immune
response are two major criteria in developing recombinant
viral vaccines against wild-type viral infections. In the last
decade, various forms of HSV replication-defective viruses
and neuroattenuated, replication-competent mutants have
been tested as potential live vaccines against HSV infection in
several different animal models (Meignier et al., 1988;
Meignier et al., 1990; Nguyen et al., 1992; Farrell et al.,
1994; McLean et al., 1994; Morrison and Knipe, 1994;
Boursnell et al., 1997; Brehm et al., 1997; Spector et al.,
1998; Walker and Leib, 1998; Da Costa et al., 1999; Keadle
et al., 2002; Osorio and Ghiasi, 2003, 2005; Prichard et al.,
2005; Parker et al., 2006). Given that both replication-
defective viruses and neuroattenuated mutants are replication
competent in the context of wild-type virus, their use as a
vaccine in humans does pose a safety concern, particularly in
individuals who harbor latent HSV infection (Koelle and
Ghiasi, 2005). Using the T-REx (Invitrogen, Carlsbad, CA)
gene switch technology developed in this laboratory and the
dominant-negative mutant polypeptide UL9-C535C of HSV-1
origin binding protein UL9, we have established a new
strategy for development of a safe and effective recombinant
HSV vaccine against HSV-1 infection. Specifically, we
constructed a replication-defective HSV recombinant,
CJ83193, capable of inhibiting the replication of wild-type
HSV-1 and HSV-2 in cell cultures (Yao and Eriksson, 1999,
2002) and in the central nervous system of mice coinoculated
with HSV-1 and CJ83193 (H Augustinova and F Yao,
unpublished data). We demonstrate further that CJ83193 is
an effective vaccine against HSV-1 infection in mice and is
capable of eliciting long-term humoral and cell-mediated
immunity comparable with that induced by wild-type HSV-1
(Augustinova et al., 2004).
HSV-1 encodes at least 12 glycoproteins, among which
gB, gC, gD, gH, and gL are most abundantly expressed in
infected cells and constitute the major HSV-1 glycoproteins
on the viral envelope (Handler et al., 1996). gD is the
major target for neutralizing antibodies against HSV infection
(Sim and Watson, 1973; Cohen et al., 1984; Para et al.,
1985; Minson et al., 1986). The role of gD in eliciting host
T-cell response has also been illustrated (Zarling et al.,
1986a, b; Koelle et al., 1994, 1998b; Mikloska and Cunning-
ham, 1998). We have shown that the expression of gD, a g
gene product, is significantly lower in CJ83193-infected cells
than cells infected with wild-type HSV-1. We thus hypo-
thesize that the vaccine efficacy of CJ83193 can be elevated
if the expression of gD can be substantially increased.
Here we describe construction of a CJ83193-derived
dominant-negative and replication-defective HSV-1 recombi-
nant, CJ9-gD, which has a deletion in the essential UL9 gene
and encodes an extra copy of the gD gene controlled by the
tetO-bearing human cytomegalovirus (hCMV) major immedi-
ate-early promoter. Thus, unlike CJ83193, which exhibits very
limited plaque-forming ability in Vero cells and expresses little
gD, CJ9-gD is completely replication defective and capable of
expressing high levels of gD in infected cells. We show that
CJ9-gD is a safer and more effective vaccine than CJ83193 in a
mouse model of HSV-1 infection.
RESULTS
Construction and in vitro characterization of CJ9-gD
To introduce the HSV-1 gD gene under control of the tetO-
hCMV IE promoter into the CJ9-lacZ genome at the UL9 locus
(Figure 1a), we transfected U2CEP4R-11 cells with 6 mg of
Mfe I-linearized p9DNATO-gD and 0.1 mg of pcDNA-UL9
followed by CJ9-lacZ superinfection at a multiplicity of
infection (MOI) of 5 PFU per cell. Progeny viruses were
harvested at 24 hours postinfection and plaque assays were
performed on RUL9-8 cell monolayers in the presence of
neutral red and X-Gal. White plaques, indicating replace-
ment of the lacZ gene by the gD gene-containing fragment of
p9DNATO-gD, were isolated and plaque purified three more
times on RUL9-8 cell monolayers. CJ9-gD is a viral
recombinant obtained after four rounds of plaque purification
that exhibits no blue plaques in plaque assay in the presence
of X-Gal, and expresses no detectable gD in infected
U2CEP4R-11 cells in the absence of tetracycline and a high
level of gD in the presence of tetracycline (F Yao et al.,
unpublished data), which demonstrates that the detected gD
expression in CJ9-gD-infected U2CEP4R-11 cells is driven by
the tetO-bearing hCMV major immediate-early promoter
(Yao et al., 1998). Western blot analysis (Figure 2a) shows
that CJ9-gD expresses significantly higher levels of gD than
CJ83193 and CJ9-lacZ in infected Vero cells. The replace-
ment of the lacZ gene by the gD gene at the UL9 locus in CJ9-
gD was confirmed by PCR analysis of CJ83193, CJ9-lacZ, and
CJ9-gD viral DNA with the UL9 sequence-specific primers
that flank the lacZ gene- and the gD gene-containing DNA
insert (data not shown). No viral plaques were detected on
Vero cell monolayers when a total of 1.1 108 PFU of CJ9-
gD virus was assayed, whereas an average of 1 plaque per
1106 PFU of CJ83193 virus was detected on Vero cell
monolayers.
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Figure 1. Schematic diagram of genomes of HSV-1 recombinant CJ9-gD. UL
and US represent the unique long and unique short regions of the HSV-1
genome, respectively, which are flanked by their corresponding inverted
repeat regions (open boxes). (a) The replacement of the ICP0 coding
sequences with DNA sequences encoding the DNA-binding domain of UL9,
UL9-C535C (black box), under control of the tetO-bearing hCMV major
immediate-early promoter (vertical line box) in CJ83193 is shown above the
diagram of the HSV-1 genome. An expanded UL9 ORF from UL9 locus is
shown below the diagram. (b) CJ9-gD was generated by replacing the Xcm I-
Mlu I fragment encoding UL9 amino acids 217–803 within the UL9 ORF in
CJ83193 with the HSV-1 gD gene under control of the tetO-bearing hCMV
immediate-early promoter. The gradient box shows the poly A signal
sequence of bovine growth hormone gene.
www.jidonline.org 1175
Z Lu et al.
A gD-Expressing Dominant-Negative HSV-1 Viral Vaccine
The results shown in Figure 2b demonstrate that a
significantly higher level of gD was detected in CJ9-gD-
infected cells than in wild-type virus KOS-infected cells at
4 hours postinfection although levels of ICP4, the major
immediate-early regulatory protein of HSV-1, were lower in
CJ9-gD-infected Vero cells than in cells infected with KOS.
Similar levels of gD were expressed in KOS- and CJ9-gD-
infected Vero cells at 6 hours postinfection.
Inhibition of wild-type HSV-1 replication by CJ9-gD
To assess the dominant-negative effect of UL9-C535C
encoded by CJ9-gD on the replication of wild-type HSV-1,
coinfection experiments were performed (Figure 3a). As
shown, coinfection of cells with CJ9-gD at an MOI of 3 and
5 PFU per cell led to a 70- and 145-fold decrease in wild-type
virus production, respectively, compared with cells singly
infected by KOS. Little reduction in wild-type virus yield was
detected when a similar coinfection experiment was per-
formed with a traditional HSV-1 replication-defective re-
combinant (Yao and Eriksson, 1999).
Figure 3b represents an experiment in which monolayers
of Vero cells were first infected with KOS at an MOI of
0.5 PFU per cell followed by superinfection with CJ9-gD or
an HSV-1 ICP4-deletion mutant, D2, at an MOI of 3 PFU per
cell at 1 hour after KOS infection. It shows that CJ9-gD can
also effectively prevent the wild-type HSV-1 infection in
preinfected cells; 54-fold less in wild-type virus synthesis was
detected in cells superinfected with CJ9-gD than in those not
superinfected, and a 2.3-fold reduction in KOS yield seen in
cells superinfected with D2 is likely because of the
cosynthesis of D2 virus in infected cells. D2 cannot form
plaque when assayed on Vero cells because of the lack of
functional ICP4 protein (DeLuca and Schaffer, 1988).
CJ9-gD is more effective than CJ83193 in induction of
anti-HSV-1 specific neutralization antibody response
We previously showed that mice immunized with CJ83193 at
a dose of 2 107 PFU per mouse had around fourfold higher
HSV-1 neutralizing antibody titer than mice immunized at a
dose of 2106 PFU per mouse (Augustinova et al., 2004; H
Augustinova and F Yao, unpublished data). To examine if
high levels of gD expression by CJ9-gD could lead to a more
effective induction of HSV-1 neutralizing antibody response,
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Figure 2. High-level expression of gD following CJ9-gD infection of Vero
cells. (a) Vero cells were seeded at 1 106 cells per 60-mm dish. At 23 hours
after seeding, cells in duplicate were either mock-infected or infected with
CJ83193, CJ9-lacZ, or CJ9-gD at an MOI of 5 PFU per cell. Infected cell
extracts were prepared at 24 hours postinfection. (b) Vero cells were infected
with the wild-type HSV-1 strain KOS, or CJ9-gD at an MOI of 20 PFU per cell.
Infected cell extracts were prepared at 4 and 6 hours postinfection. Proteins in
infected cell extracts were resolved on SDS–PAGE, followed by
immunoblotting with a monoclonal antibody specific for ICP4 or a polyclonal
antibody specific for gD.
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Figure 3. Trans-dominant-negative effect of CJ9-gD on replication of wild-
type herpes simplex virus type 1 (HSV-1). Vero cells were seeded at 7.5 105
per 60-mm dish. (a) At 24 hours postseeding, cells in triplicate were infected
with either wild-type HSV-1 strain KOS at an MOI of 1 PFU per cell, KOS at
an MOI of 1 PFU per cell and CJ9-gD at an MOI of 3 PFU per cell, or KOS at
an MOI of 1 PFU per cell and CJ9-gD at an MOI of 5 PFU per cell. (b) Vero
cells were infected with wild-type HSV-1 strain KOS at an MOI of 0.5 PFU per
cell. At 1 hours postinfection, cells were either mock superinfected or
superinfected with CJ9-gD, or an ICP4-deletion mutant, D2, at an MOI of
3 PFU per cell. Infected cells were harvested at 18 hours postwild-type HSV-1
infection and viral titers were determined on Vero cell monolayers. Viral titers
are expressed as the mean±SD. Numbers on the top of the graph indicate the
fold of reduction in wild-type virus yield between single infection and
coinfection.
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mice were either mock immunized or immunized with
CJ83193 or CJ9-gD at a dose of 2106 PFU per mouse. The
results (Figure 4a) demonstrate that immunization with CJ9-
gD elicited an average of 3.5-fold and 2-fold higher anti-
HSV-1 specific neutralizing antibody titer than that of mice
immunized with CJ83193 (P¼0.0065, unpaired t-test) and
CJ9-lacZ (P¼0.02, unpaired t-test), respectively. CJ9-gD
induced the same level of anti-HSV-1 specific neutralizing
antibodies as wild-type HSV-1 KOS in mice (data not shown,
R Brans and F Yao, unpublished work). The HSV-1
neutralizing antibody titer detected in the mock-immunized
control was less than 2 (data not shown).
Figure 4b shows that levels of anti-gD-specific antibodies
in mice immunized with CJ9-gD were much higher than
those detected in mouse serum from CJ83193 and CJ9-lacZ-
immunized mice and is at levels similar to those induced in
mice immunized with the wild-type HSV-1 KOS, suggesting
that the elevated neutralization antibody titer in CJ9-gD
immunized mice is the direct result of more efficient
induction of anti-gD-specific antibodies. The enhanced
effectiveness of CJ9-gD in induction of HSV-1 neutralizing
antibodies has been further confirmed by the finding that CJ9-
gD at a dose of 1105 PFU per mouse elicits twofold higher
HSV-1 neutralizing antibody titer than CJ83193 at a dose of
5105 PFU per mouse (R Brans and F Yao, unpublished
work).
We next examined the effectiveness of CJ9-gD in
induction of HSV-1-specific T-cell immune response with
cytokine assays (Figure 5a) and CD4þ T cell (Figure 5b) and
CD8þ T cell (Figure 5c) IFN-g ELISPOT. Although less
effective than wild-type HSV-1 (P¼0.138, statistically insig-
nificant), immunization with CJ9-gD led to a significant
induction of HSV-1-specific IFN-g response compared with a
mock-immunized control (5,768 vs 301 pgml1, P¼0.014,
unpaired t-test; Figure 5a). Similar levels of IL-2 response
were detected in CJ9-gD and wild-type HSV-1 immunized
mice, and the difference in levels of IL-2 expression between
CJ9-gD- and CJ83193-immunized mice was statistically
insignificant. No statistical difference was seen in induction
of IL-4 response among mock-immunized mice and mice
immunized with KOS, CJ9-gD, and CJ83193 (Figure 5a). In a
separate experiment (data not shown) in which CJ9-gD and
CJ9-lacZ were compared directly, IFN-g response was
similar, whereas higher IL-2 production was seen in CJ9-gD
immunized mice (P¼0.56, statistically insignificant).
IFN-g ELISPOT assays (Figure 5b) demonstrate that
immunization with CJ9-gD elicited an HSV-1-specific
CD4þ T-cell response similar to that seen in wild-type
HSV-1, yielding 20-fold more IFN-g spot-forming cells (SFCs)
than the mock-immunized control (P¼0.002). HSV-1-spe-
cific CD8þ T-cell response (Figure 5c) was comparable
between mice immunized with KOS and CJ9-gD (P¼0.07,
statistically insignificant). Taken together, the results demon-
strate that, like wild-type HSV-1, immunization with CJ9-gD
can effectively elicit HSV-1-specfic Th1 T-cell response.
Effect of immunization with CJ9-gD on acute viral replication
and reactivation of latent infection by wild-type HSV-1
Four weeks after the initial immunization, individual groups
of mice (n¼12) were challenged with HSV-1 strain mP
following corneal scarification and eye swabs were taken on
days 5 and 7 postchallenge. The degree of replication of
challenge virus in trigeminal ganglia (TG) of mock-immu-
nized and immunized mice was examined on day 6
postchallenge. Immunization with CJ83193, CJ9-lacZ, and
CJ9-gD significantly reduced the replication of challenge
virus in the eyes of immunized mice compared with the
mock-immunized control on day 5 postchallenge (Figure 6a).
No challenge virus was detectable in eye swabs collected
from immunized mice on day 7 postchallenge. On day 5 after
challenge, the yield of challenge virus in eye swabs of
mice immunized with mock-infected cell lysate was
13,410 PFUml1, and no challenge virus was detected in
eye swabs of mice immunized with CJ9-gD. An average of
21.25 and 6.87 PFUml1 of challenge virus was detected in
mice immunized with CJ83193 and CJ9-lacZ, respectively.
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Figure 4. Induction of herpes simplex virus type 1 (HSV-1)-specific
neutralizing and gD-specific antibodies. (a) Blood was obtained from the tail
veins of mice 4 weeks after primary immunization. Serum from mice
immunized with CJ8319 (n¼4–7) and CJ9-gD (n¼ 4–16) was pooled and heat
inactivated. A series of twofold dilutions of serum was made in normal growth
medium in the presence of Low Tox M rabbit C. Two hundred fifty plaque-
forming units of wild-type HSV-1 was added to each tube containing diluted
serum and to control tubes containing titration growth medium and Low Tox
M rabbit C in a final volume of 600 ml. The neutralizing titers were calculated
as the final serum dilution leading to a 50% reduction in the number of HSV-1
PFU compared with that obtained in media plus complement alone. The
graph represents results (the mean value±SD) from four independent
experiments, which contained at least four mice per group. The titer of HSV-1
neutralizing antibody in mock-immunized mice was less than 2. (b) Individual
groups of female BALB/c mice (n¼8) were immunized with mock-infected
cell lysate, CJ83193, CJ9-lacZ, CJ9-gD, or KOS at 2 106 PFU per mouse as
described. Four weeks after primary immunization, blood was obtained from
tail veins of mice and pooled. Sera from individual groups of mice were
incubated with cell extract prepared from p9DNATO-gD transfected U2OS
cells. gD/mouse IgG-specific complexes were precipitated with protein A
(Immunoprecipitation Starter Pack; Amersham Biosciences), resolved on
SDS–PAGE, and probed with a gD-specific polyclonal antibody.
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The yield of challenge virus in TG of mock-immunized
mice on day 6 was 5,728 PFUml1, and no challenge virus
was detected in TG of CJ9-lacZ- and CJ9-gD-immunized
mice (Figure 6b). Among eight TG harvested from CJ83193-
immunized mice, one ganglion showed detectable challenge
virus at 2 PFUml1 and no virus was present in the remaining
seven TG. In a similar experiment, we detected no challenge
virus in TG (n¼ 8) among all immunized mice harvested on
day 6 postchallenge (data not shown). Collectively, these
results demonstrate that CJ9-gD is more effective than
CJ83193 in prevention of acute replication of challenge
wild-type HSV-1 in the corneal surface and TG of immunized
mice.
Figure 7a shows a representative of two independent
experiments that demonstrate that immunization with
CJ9-gD can completely prevent the development of the
HSV-induced keratitis by challenge virus (n¼16), whereas a
minor challenge virus-induced keratitis was observed in
CJ83193- and CJ9-lacZ-immunized mice (n¼ 16) in the
described experiments. It should be noted that all mock-
immunized mice (n¼ 22) developed signs of encephalitis,
and 18 mice died by day 12 postchallenge. No signs of virus-
induced encephalitis were seen in immunized mice
(n¼20–22).
Cocultivation assays of TG harvested from mock-immu-
nized and immunized mice (Figure 7b) indicate that
immunization with CJ83193, CJ9-lacZ, and CJ9-gD led to a
69, 75, and 80% lower reactivation of the challenge virus,
respectively, than in mock-immunized control mice.
CJ9-gD cannot establish detectable infection in the trigeminal
ganglia of mice following intranasal and ocular inoculation
Da Costa et al. (1999) showed that deletion of two essential
viral genes whose function is required for HSV-2 viral DNA
replication could render the resulting viral recombinant dl5-
29 unable to establish a stable latent infection in the TG of
infected mice following intranasal inoculation of 1 106 PFU
per mouse. Considering that CJ9-gD has a deletion in the
essential UL9 gene and expresses a dominant-negative UL9-
C535C polypeptide, which lead to either blocking (UL9
deletion) or significantly inhibit (UL9-C535C expression) viral
replication, we examined whether CJ9-gD can establish
latent infection in mice after intranasal and ocular inocula-
tion. As shown (Figure 8), whereas significant amounts of
KOS DNA were present in TG DNA isolated from KOS
inoculated mice, no viral DNA was detected in TG DNA of
mice intranasally inoculated with CJ83193 and CJ9-gD
(Figure 8a). We did, however, detect an average of 8.3
copies per TG of CJ83193 viral DNA following ocular
inoculation. Again, no CJ9-gD viral DNA was detectable in
TG DNA of mice inoculated with CJ9-gD (Figure 8b). These
results indicate that CJ9-gD cannot establish a detectable
infection in the TG of infected mice.
DISCUSSION
We constructed a new generation of dominant-negative and
replication-defective HSV-1 recombinant, CJ9-gD, which has
the essential UL9 gene deleted and encodes an extra copy of
the gD gene under control of the tetO-bearing hCMV major
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Figure 5. Induction of HSV-1-specific T-cell response in CJ9-gD-immunized mice. Cytokine assays (a). Female BALB/c mice were immunized with either mock-
infected cell lysate, KOS, CJ9-gD or CJ83193 at 2 106 PFU per mouse. Splenocytes were isolated individually from mock-immunized (n¼4) and immunized
mice (n¼4), and seeded in 24-well plates at 1.5106 cells per well. Cells in duplicate were mock stimulated or stimulated with UV-inactivated HSV-1 strain
McKrae. Extracellular medium was collected at 72 hours poststimulation and levels of IFN-g, IL-2, and IL-4 were determined. Cytokine production is presented
as the mean concentration±SEM in splenocytes isolated from four mice per group. IFN-g ELISPOT assays (b, c). Splenocytes were prepared individually from
mice (n¼ 4) either mock-immunized or immunized with KOS or CJ9-gD. For CD4þ T-cell ELISPOT (b), CD4þ T cells were isolated from splenocytes using
Dynal mouse CD-negative kit, and seeded in 96-well MultiScreen HTS, IP sterile white filtration plates precoated with antimouse IFN-g specific monoclonal
antibody (AN18) at 5 104 and 1.5105 cells per well. Cells in triplicate were stimulated with mock-infected or UV-inactivated HSV-1 strain McKrae-infected
and mitomycin C-treated syngeneic CD11cþ BM-DCs. For detection of HSV-1-specific CD8þ T cells (c), splenocytes seeded in triplicate wells of 96-well
filtration plates precoated with monoclonal antibody AN18 were stimulated with either mock-infected or HSV-1 strain McKrae-infected and mitomycin
C-treated syngeneic CL7 cells. The IFN-g spot-forming cells were detected as described in ‘‘Materials and Methods’’ section. The HSV-1-specific IFN-g spot-
forming cells (SFC) are expressed as the mean±SEM per million splenocytes from four mice per group.
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immediate-early promoter. Because this promoter is fully
functional in the context of the HSV-1 genome during acute
viral infection and is independent of HSV-1 viral DNA
replication (Stinski and Roehr, 1985; Johnson et al., 1992;
Mester et al., 1995; Marconi et al., 1996; Yao and Eriksson,
1999), this design allows high and immediate-early expres-
sion of gD after CJ9-gD enters the cell. Indeed, CJ9-gD
expresses much higher levels of gD than CJ83193 and CJ9-
lacZ (Figure 2a). We further showed that significantly higher
amounts of gD were expressed in CJ9-gD-infected cells than
that of wild-type virus-infected cells at 4 hour postinfection.
CJ9-gD represents the first genetically engineered HSV
recombinant that expresses gD at the immediate-early phase
of viral infection.
In addition to the tetO-bearing hCMV immediate-early
promoter-driven gD gene inserted at the UL9 locus in the
unique long region of the HSV-1 genome (Figure 1), CJ9-gD
retains the endogenous copy of gD gene in the unique short
region of the viral genome. We have recently replaced the
HSV-1 ICP47 gene with the lacZ gene in CJ9-gD (R Brans
et al., unpublished study). Given that several lacZ-expressing
CJ9-gD isolates express similar levels of gD as CJ9-gD in
infected Vero cells, and yields of CJ9-gD and CJ9-lacZ in
RUL9-8 cells are similar, it seems that a single crossover
homologous recombination between the two gD coding
sequences within the CJ9-gD genome, which could lead to a
replication-defective viral recombinant, is not a major factor
that could influence the genetic stability of CJ9-gD.
Alternatively, one can delete the endogenous copy of gD
gene from the unique short region of CJ9-gD to eliminate this
potential genetic instability.
Although CJ83193 cannot initiate acute productive infec-
tion in corneas of infected mice, nor can it reactivate from TG
of mice latently infected by CJ83193 (Augustinova et al.,
2004), CJ83193 does, however, possess a limited plaque-
forming ability in Vero cells (Augustinova et al., 2004). This
study shows that CJ9-gD is completely replication defective
in Vero cells. We detected no CJ9-gD viral DNA in the TG of
mice inoculated by CJ9-gD following corneal inoculation
under the described conditions, whereas limited copies of
CJ83193 viral DNA were detected in the TG of mice
inoculated with CJ83193. These results suggest that CJ9-gD
is safer than CJ83193 as a vaccine candidate in clinical
applications. It is worth noting that because CJ9-gD expresses
high levels of the dominant-negative UL9-C535C polypeptide
in normal cells, lacks the essential UL9 gene, and possesses a
unique capability in inhibiting wild-type HSV infection in
coinfected cells as well as cells first infected with wild-type
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Figure 6. Reduction of challenge wild-type HSV-1 replication in the eye and
trigeminal ganglion of immunized mice. Female BALB/c mice were randomly
divided into four groups of 12 mice each and immunized with either mock-
infected cell lysate or CJ83193, CJ9-lacZ, or CJ9-gD as described. Four weeks
after primary immunization, mice in all groups were challenged following
corneal scarification with 2 105 PFU per eye of HSV-1 strain mP. Eye swabs
were taken on days 5 and 7 postchallenge, whereas mouse trigeminal ganglia
(n¼8) were prepared on day 6 postchallenge. Infectious viruses in individual
eye-swab materials (a) and trigeminal ganglia (b) were assessed by standard
plaque assay on Vero cell monolayers. Viral titers are expressed as the
mean±SEM in individual eye swabs and trigeminal ganglia of mice per
group.
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Figure 7. Prevention of herpetic keratitis and establishment of latent
infection by challenge virus in immunized mice. (a) Female BALB/c mice
were randomly divided into four groups of eight mice each and immunized
with mock-infected cell lysate, CJ83193, CJ9-lacZ, or CJ9-gD as described.
Four weeks after initial immunization, both eyes of the mice were challenged
with HSV-1 strain mP following corneal scarification. Individual eyes were
scored for severity of keratitis during a 30-day follow-up period. The indicated
values represent the mean score±SEM of all eyes from each group of mice.
(b) Mice described in panel A and from a similar experiment in which mice
were immunized with either mock-infected cell lysate (n¼ 10), CJ83193
(n¼8), CJ9-lacZ (n¼ 8), or CJ9-gD (n¼ 10) were killed 30 days after
challenge. Trigeminal ganglia of mice from different groups were processed
and cocultivated individually onto Vero cell monolayers. After 5 days of
cocultivation, explants were harvested, processed, and assayed on Vero cell
monolayers for the presence of infectious viruses.
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HSV-1 (Figure 3), it is reasonable to believe that CJ9-gD will
be a safer vaccine candidate, at least in theory, than
traditional replication-defective HSV recombinants that con-
tain recessive mutations, particularly should recombinant
viral vaccines be used as a therapeutic vaccine for recurrent
HSV infection (Koelle and Ghiasi, 2005).
The effectiveness of CJ9-gD as a vaccine against wild-type
HSV-1 infection was examined in a mouse model of HSV-1
infection. Mice immunized with CJ9-gD produce 3.5-fold
higher anti-HSV-1-specific neutralizing antibodies than those
detected in serum of CJ83193-immunized mice and at the
same level as that induced in mice immunized with the wild-
type HSV-1 KOS (Z Lu et al., unpublished data, R Brans et al.,
unpublished work). It is further demonstrated that CJ9-gD is
more efficient in inducing anti-gD-specific antibodies than
CJ83193 and CJ9-lacZ in mice. We demonstrate that
immunization with CJ9-gD elicits a similar degree of HSV-
1-specific T-cell response as KOS-immunized mice (Figure 5).
Consistent with these observations, mice immunized with
CJ9-gD exhibited complete protection from herpetic disease
following corneal challenge with wild-type HSV-1. The
efficacy of CJ9-gD as an effective vaccine in prevention of
HSV-1-induced genital disease has also been demonstrated in
a mouse model of HSV-1 genital infection (R Brans and F
Yao, unpublished work). We show further that CJ9-gD is
significantly more effective than CJ83193 in protecting mice
from HSV-1 genital infection. In the this study we detected no
statistical difference in induction of IFN-g and IL-2 responses
between KOS and CJ9-gD, CJ9-gD and CJ83193 (Figure 5a),
or CJ9-gD and CJ9-lacZ (data not shown), suggesting that,
compared with its dominant role in induction of HSV-1-
specific neutralizing antibody response, gD does not appear
to be involved in eliciting overall HSV-1-specific Th-1 T-cell
response during HSV-1 infection and/or following immuniza-
tion with CJ9-gD in mice. This is probably not surprising,
given that in addition to gD, CJ9-gD is capable of expressing
various viral a, b, and g1 gene products that effectively elicit
T-cell responses (Koelle et al., 1994, 1998a, 2001; Mikloska
and Cunningham, 1998; Mikloska et al., 2000), whereas gD
is one of only four essential HSV-1 glycoproteins on the virus
envelope that are required for virus to enter cells. Lastly, this
study indicates that immunization with CJ9-gD can lead to a
significant reduction in reactivation efficiency of the chal-
lenge virus in immunized mice (20%) compared with mock-
immunized controls (100%). Consistent with this observation,
we recently showed that immunization with CJ9-gD prevents
recurrent genital infection and disease in guinea pigs (R Brans
and F Yao, unpublished work) and significantly reduces the
frequency and magnitude of latent infection by the challenge
wild-type HSV-1 in a guinea pig model of HSV-1 skin
infection (Brans et al., 2008).
HSV-1 evolves several different strategies to evade host
immune responses (Dubin et al., 1991; York et al., 1994; Fruh
et al., 1995; Hill et al., 1995; He et al., 1997; Eidson et al.,
2002; Sievers et al., 2002). ICP0 and ICP47 are the two HSV
immediate-early proteins directly involved in host immune
evasion following viral infection. ICP0 is involved in blocking
IFN-induced inhibition of viral infection (Eidson et al., 2002),
whereas ICP47 downregulates the major histocompatibility
complex class I expression on the surface of infected cells
(York et al., 1994; Fruh et al., 1995; Hill et al., 1995). The
ability of CJ9-gD to express high levels of gD at the
immediate-early phase of infection could lead to effective
presentation of gD-specific peptide–major histocompatibility
complex class I complexes at the cell surface before the onset
of inhibition of ICP47 on major histocompatibility complex
class I antigen presentation. Because ICP47 binds poorly to
mouse and other murine transporter-associated protein and is
unable to block peptide transport and antigen presentation in
mouse cells, the potential advantage of immediate-early
expression of gD by CJ9-gD may not be fully appreciated in
the tested mouse model. In addition, considering the recently
identified function of an HSV-1 delayed-early gene product,
gB, in downregulating the major histocompatibility complex
class II antigen presentation in infected cells (Neumann et al.,
2003) as well as the potential interference on antigen
presentation by other HSV-encoded immune evasion mole-
cules (Rouse and Kaistha, 2006), one can speculate that
immediate-early expression of gD by CJ9-gD might elicit a
more effective and potent gD-specific T-cell immune
response than an HSV recombinant virus that expresses gD
at the delayed-early phase of infection. This hypothesis is
supported by an earlier study of Wachsman et al., which
showed that immunization with vaccinia virus expressing
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Figure 8. CJ9-gD cannot establish detectable infection in the mouse
trigeminal ganglia after intranasal and ocular inoculation. CD-1 mice were
randomly assigned to five groups of 8–10 mice each and inoculated either
intranasally (a) or ocularly after corneal scarification (b) at a dose of
1.5 106 PFU per nasal and 2106 PFU per eye with KOS, 7134, d27,
CJ83193, or CJ9-gD. As a negative control, CD-1 mice were also inoculated
in a similar fashion with DMEM. Individual TG DNA was isolated on day 3
postinoculation followed by real-time PCR analysis with primers specific to
the HSV-1 DNA polymerase.
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HSV-1 gD by a viral early promoter was significantly more
effective in induction of T-cell response as well as in
protecting guinea pigs from wild-type HSV-2 infection
than the vaccinia virus expressing gD under control of a
viral late promoter, albeit two viral recombinants were
capable of expressing similar levels of gD (Wachsman
et al., 1989).
MATERIALS AND METHODS
Cells
African green monkey kidney (Vero) cells and the osteosarcoma line
U2OS cells were grown and maintained in DMEM (Sigma Aldrich,
St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) in
the presence of 100Uml1 penicillin G and 100mgml1 strepto-
mycin sulfate (GIBCO, Carlsbad, CA; Yao and Schaffer, 1995).
U2OS cells are able to complement functionally for the HSV-1 ICP0
deletion (Yao and Schaffer, 1995). U2CEP4R11 cells are tetR-
expressing U2OS cells that were maintained in DMEM plus 10% FBS
and hygromycin B at 50 mgml1 (Yao et al., 1998). RUL9-8 cells
were UL9-expressing U2CEP4R11 cells that were grown and
maintained in DMEM plus 10% FBS supplemented with hygromycin
B (50 mgml1) and G418 (400mgml1; Yao et al., 2006).
Plasmids
pcDNA-UL9 expresses UL9 from the HSV-1 UL9 promoter with the
bovine growth hormone polyadenylation signal sequence at its 30
end (Yao et al., 2006). Plasmid pUL9BX-lacZ was generated by
replacing the Xcm I-Bam HI fragment within the UL9 open reading
frame in pcDNA-UL9 with DNA sequences encoding the lacZ gene
under the control of the hCMV major immediate-early promoter with
the SV40 poly A signal at the 30 end of the lacZ gene. The Xcm I-Bam
HI fragment encodes UL9 amino acids 217–535. pUL9-V is a
derivative of pcDNA-UL9 with a deletion of a 17-bp Not I-Xba I
fragment present in pcDNA3. Plasmid p9DNATO-B was constructed
by replacing the Xcm I-Mlu I fragment containing UL9 amino acids
217–803 in plasmid pUL9-V with the Mlu I-Pvu II DNA fragment
consisting of the tetO-hCMV-MCS-poly A transcription unit of
pCDNA4-TO (Invitrogen). Plasmid p9DNATO-gD expresses the
HSV-1 gD gene under control of the tetO-bearing hCMV major
immediate-early promoter, which contains the Hind III-Ple I-gD
gene-encoding fragment of pRE4 (the kind gift of Gary H. Cohen and
Roselyn J. Eisenberg, University of Pennsylvania) in p9DNATO-B at
the Hind III and Pme I sites.
Viruses
Wild-type HSV-1 strains, KOS, and mP were propagated and
plaque assayed on Vero cells (Augustinova et al., 2004). CJ83193
is an HSV-1 recombinant in which both copies of the ICP0 gene are
replaced by DNA sequences encoding UL9-C535C under the
control of the tetO-bearing hCMV major immediate-early promoter
(Figure 1a; Yao and Eriksson, 1999). It was propagated and assayed
in U2CEP4R11 cells (Yao and Eriksson, 1999). D2, a KOS-derived
ICP4-deletion mutant, was propagated and assayed in ICP4-
expressing E5 cells (DeLuca and Schaffer, 1988). CJ9-lacZ was
generated by replacing the essential UL9 gene in CJ83193 with the
lacZ gene under control of the hCMV major immediate-early
promoter using plasmid pUL9BX-lacZ (C Theopold et al., unpub-
lished data).
SDS–PAGE and Western blot analysis
Vero cells seeded in 100mm dishes at 2 106 cells per dish were
mock-infected or infected with indicated viruses at MOIs of 5 or
20 PFU per cell. Cell extracts were prepared at 4, 6, or 15 hours
postinfection (Yao and Schaffer, 1994). Proteins in the cell extract
were resolved by SDS–PAGE (9% acrylamide), transferred to
polyvinylidene difluoride membranes, and probed with either a
monoclonal antibody specific for HSV-1 immediate-early protein
ICP4 (Fitzgerald Industries International Inc., Concord, MA) or a
rabbit polyclonal antibody (R45) specific for gD as described
previously (Yao and Schaffer, 1994). R45 was the kind gift of Dr.
Gary H. Cohen and Dr. Roselyn J. Eisenberg.
Mice
CD-1 mice and female BALB/c mice 6–8 weeks of age were
purchased from Charles River Laboratories (Wilmington, MA). Mice
were housed in metal cages at four mice per cage and maintained on
a 12-hours light/dark cycle. Mice were allowed to acclimatize to the
housing conditions for 1 week before experimentation. All animal
experiments were conducted according to the protocols approved by
Harvard Medical Area Standing Committee on Animals and the
American Veterinary Medical association.
Acute infection and real-time PCR
CD-1 mice were anesthetized with sodium pentobarbital. Wild-type
HSV-1 and HSV-1 recombinant viruses at indicated doses in a
volume of 10 ml were inoculated either intranasally or to the eye after
corneal scarification (Leib et al., 1989; Augustinova et al., 2004).
Individual TG were harvested on day 3 postinoculation and TG DNA
was isolated with the DNeasy Tissue kit (Qiagen, Germantown, MD)
and suspended in 60 ml of AE buffer. The presence of HSV-1 viral
DNA was quantified by real-time PCR with a pair of primers specific
to the HSV-1 DNA polymerase (forward: 50-GCTCGAGTGCGAA
AAAACGTTC, reverse: 50-CGGGGCGCTCGGCTAAC) as previously
described (Aldea et al., 2002; Brans et al., 2008). The minimal
copies of HSV-1 viral DNA that can be reliably detected were five
copies per reaction.
Immunizations and challenges
Six to eight-week-old female BALB/c mice were randomly divided
into several groups and were immunized with either mock-infected
cell lysate, KOS, CJ83193, CJ9-lacZ, or CJ9-gD at 2 106 PFU
per mouse in a 20 ml volume s.c. with a 26-gauge needle. Mice
were boosted s.c. with the same virus 2 weeks after primary
immunization. Four weeks after the initial immunization, mice in all
groups were challenged following corneal scarification with
2 105PFU of HSV-1 strain mP per eye in a 10ml volume (Morrison
and Knipe, 1994). The ability of the challenge virus to cause acute
infection in the eyes and TG at indicated time points was assayed on
Vero cell monolayers as described previously (Augustinova et al., 2004).
In vitro cocultivation assays were used for measuring the
reactivation efficiency of challenge virus in mock vaccinated and
vaccinated mice 30 days after challenge with wild-type HSV-1 (Leib
et al., 1989; Augustinova et al., 2004). In brief, at 30 days
postchallenge, each TG of mice from different groups was processed
and cocultivated individually onto Vero cell monolayers (Leib et al.,
1989; Augustinova et al., 2004). After 5 days of cocultivation,
explants were harvested and assayed on Vero cell monolayers for the
presence of infectious viruses.
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Detection of HSV-1 neutralization antibodies
Blood was obtained from the tail veins of immunized or mock-
immunized mice 1 day before immunization and 28–30 days after
primary immunization. Neutralizing serum Ab titers were deter-
mined in the presence of complement and expressed as the final
serum dilution leading to a 50% reduction in HSV-1 PFU relative to
the HSV-1 PFU obtained in medium in the presence of complement
(Bourne et al., 1996b; Augustinova et al., 2004).
Immunoprecipitation
U2OS cells seeded at 1 106 cells per 100-mm dish were mock-
transfected or transfected with 10 ug of p9DNATO-gD by lipofecta-
mine 2000 at 24 hours postseeding. Cell extracts were prepared at
24 hours posttransfection (Yao and Schaffer, 1994). Immunoprecipi-
tations were performed by mixing 5 ml of pooled serum collected
from mock-immunized and immunized mice with 200 ml of cell
extracts prepared above. The gD/mouse IgG-specific complexes
were precipitated with protein A (Immunoprecipitation Starter Pack;
Amersham Biosciences, Piscataway, NJ), resolved on SDS–PAGE and
probed with the anti-gD-specific polyclonal antibody, R45.
Cytokine assay
Two weeks after the second immunization, the spleens of
immunized and mock-immunized mice were removed, and single
cell suspensions were prepared by grinding spleens with two sterile
glass slides. After removal of tissue debris and treatment of cell
suspensions with ACK lysis buffer (0.15 M NH4Cl, 1mM KHCO3,
0.1mM Na2EDTA, pH 7.2–7.4), cells were resuspended in DMEM/L-
glutamine-plus complete medium (10% heat-inactivated FBS,
100Uml1 penicillin, 100mgml1 streptomycin, 5mM 2-mercap-
toethanol, and 1% nonessential amino acid) followed by Ficoll-
Paque Plus (Amersham Biosciences) gradient isolation of lympho-
cytes. Cells were then seeded into 24-well plates at 1 106 cells per
well in a volume of 1ml. Cells in triplicate were either mock
stimulated with medium or with UV-inactivated HSV-1 strain
McKrae, at an MOI of 5 PFU per cell according to the titer before
UV inactivation. As a positive control, cells in triplicate were
stimulated with Con A at 2.5mg/1 106 cells per ml. Cells were
incubated at 37 1C and the supernatant was collected at 72 hours
poststimulation and stored at 80 1C. Levels of IFN-g, IL-2, and IL-4
were determined by an ELISA kit specific for mouse IFN-g, IL-2, or
IL-4 (Endogen; Pierce Biotechnology Inc., Rockford, IL).
IFN-c ELISPOT assay
Splenocytes were isolated individually from mice either mock-
immunized or immunized with KOS or CJ9-gD 10–12 weeks after
primary immunization as described above. For CD4þ T-cell
ELISPOT assays, CD4þ T cells were isolated from splenocytes using
Dynal mouse CD-negative kit and seeded in 96-well MultiScreen
HTS, IP sterile white filtration plates (Millipore Co., Billerica, MA)
precoated with antimouse IFN-g specific monoclonal antibody
(AN18, 3321-3; Mabtech Inc., Cincinnati, OH) at 5 104 and
1.5 105 cells per well. Cells in triplicate were either stimulated
with mock-infected or UV-inactivated HSV-1 strain McKrae-infected
(5 PFU per cell) and mitomycin C-treated (50 mgml1) syngeneic
CD11cþ bone marrow-derived dendritic cells (BM-DCs) at respon-
der-to-stimulator ratios of 5:1 and 10:1, respectively. BM-DCs were
prepared from BM cells harvested from femurs and tibias of female
BALB/c mice and cultured for 8–10 days with RPMI-1640 complete
medium (10% heat-inactivated FBS, 100Uml1 penicillin,
100mgml1 streptomycin, 50 mM 2-mercaptoethanol, 2mM L-gluta-
mine) in the presence of GM-CSF at 20 ngml1 (PeproTech Inc.,
Rocky Hill, NJ) according to the protocol described by Lutz et al.
(1999). Flow cytometric analysis using phycoerythrin-labeled
CD11cþ mouse-specific antibody shows that nearly 60% of day 7
and 65% of day 11 nonadherent cells in BM culture were CD11cþ
DCs. For detection of HSV-1-specific CD8þ T cells, splenocytes
isolated from mock-immunized and immunized mice were seeded
in 96-well filtration plates precoated with antimouse IFN-g specific
monoclonal antibody (AN18) at 5 104 and 1.5 105 cells per well.
Cells in triplicate were stimulated with either mock-infected or HSV-
1 strain McKrae-infected (1 PFU per cell) and mitomycin C-treated
(50 mgml1) syngeneic CL7 cells (ATCC, Manassas, VA) at respon-
der-to-stimulator ratios of 2:1 and 5:1, respectively. After incubation
at 37 1C for 24 hours, wells were washed with phosphate-buffered
saline containing 0.05% Tween 20 followed by reaction with
biotinylated IFN-g specific monoclonal antibody (R4-6A2; Mabtech
Inc.) at 250 ng per well at room temperature for 2 hours. After
incubation with streptavidin-alkaline phosphatase (Mabtech Inc.),
the IFN-g SFCs were detected by addition of 5-bromo-4-chloro-30-
indolyphosphate p-toluidine/nitro-blue tetrazolium chloride sub-
strate. Spots were counted in a dissecting microscope and the
number of HSV-1-specific IFN-g SFCs was expressed as the
mean±SEM per million splenocytes minus the SFC detected in the
corresponding control wells stimulated with mock-infected BM-DCs
or CL7 cells.
Clinical observations
Following immunization and subsequent challenge with wild-type
HSV-1 strain mP, mice were observed daily during a 30-day follow-
up period for signs of clinical illness (Augustinova et al., 2004). Eyes
were examined with an ophthalmoscope for evidence of keratitis
and scored for severity of disease (scale 0–4). The mean keratitis
score for each group of mice was determined. A score of 0 represents
a clear cornea; 1, 2, and 3 indicate corneal opacity from mild (less
than 25% of corneal surface) to moderate (25–50% of cornea
surface) and severe (50–75% of corneal surface), respectively. A
score of 4 indicates total opacity of cornea with no posterior view.
Statistical analysis
For statistical analysis Student’s t-tests were performed. Results are
considered to be statistically insignicant when the P-value is greater
than 0.05.
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